ReviewCurrent gene therapy2026
Targeting of YKL-40 as a Protumor in Personalized Medicine: A New Dimension in Disease Understanding.
Review in Current gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- FOXP Transcription Factors in Thyroid Cancer: From Molecular Expression to Clinical Significance.Biomedicines · 2026Review
- Overexpression of ANAPC1 Affects the Cell Cycle Pathway to Promote the Progression of Lung Adenocarcinoma.Combinatorial chemistry & high throughput screening · 2026Article
- Exploring the mechanism of Yi Qi Huo Xue compound prescription in treating chronic heart failure based on integrated network pharmacology and transcriptomics.Frontiers in cardiovascular medicine · 2026Article
- Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy.Frontiers in immunology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividualization of the therapeutic plan for cancer patients is the essence of modern clinical practice. Standard cancer diagnostic and prognostic factors are invasive, and their value for the stratification of cancer patients with a higher risk of local or distant recurrence is limited. YKL-40 is a protumor glycoprotein linked to the immunosuppressive tumor in a microenvironment and an important biomarker of cell activation, proliferation, and migration.
objectiveThe objective is to update the review, and molecular and clinical research should investigate novel modalities of targeting this glycoprotein for cancer treatment.
methodsRelevant studies published in the English language were identified by searching PubMed, Google Scholar, and MEDLINE from January 2000 to December 2023. Published studies that specifically elicited the role of YKL-40 as a biomarker in different types of tumors were included.
resultsYKL-40 cancer prognostic effect was reported in various cancer types.
conclusionSince antibodies against YKL-40 can inhibit tumor angiogenesis and cancer progression, it can be suggested as an attractive candidate for chemical cancer therapy and immunomodulation.
Indexed as
Identifiers
39976089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.